

October 5, 2026

The Secretary,
Listing Department,
BSE Limited,
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
Scrip Code: 531642

The Manager,
Listing Department,
The National Stock Exchange of India Limited,
'Exchange Plaza', C-1 Block G,
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051
Scrip Symbol: MARICO

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
("SEBI Listing Regulations")

We refer to our letters dated July 26, 2023, November 30, 2023, May 31, 2025 and December 17, 2025, informing that Marico Limited ("**Company**" / "**Marico**") has acquired an aggregate of 60% stake on a fully diluted basis in Satiya Nutraceuticals Private Limited ("**Satiya Nutraceuticals**"), a subsidiary that owns the brand "**PLIX**", and further has a right under the definitive agreement(s) to acquire the remaining 40% stake, subject to certain terms and conditions.

Pursuant to the above, the Company has entered into definitive agreement(s) to acquire 38.18% stake in Satiya Nutraceuticals on a fully diluted basis, in tranches, from its Founders and certain other shareholders as per terms and conditions agreed therein. As part of the aforesaid transaction, the Company has currently acquired 24.09% stake in Satiya Nutraceuticals, thereby increasing its aggregate stake from 60% to 84.09% on a fully diluted basis.

In this regard, requisite disclosure under Regulation 30 of the SEBI Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 (as amended) is enclosed as Annexure.

This intimation is also being made available on the Company's website at:
<http://marico.com/india/investors/documentation/shareholder-info>.

Kindly take the same on record.

Yours faithfully,

For **Marico Limited**

VINAY M
A

Digitally signed by
VINAY M A
Date: 2026.10.05
20:05:38 +05'30'

Vinay M A

Company Secretary & Compliance Officer

Encl.: As above

Annexure

Disclosure under sub-para (1) [i.e. Acquisition(s) (including agreement to acquire)] of Para (A) of Part (A) of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Description
1.	Name and details of the target entity	Satiya Nutraceuticals Private Limited (“ Satiya Nutraceuticals ”), and its wholly owned subsidiary, Juizo Advisory Private Limited (“ Juizo ”).
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	Yes, the acquisition by the Company of stake held by the Founders of Satiya Nutraceuticals and their relatives/related entities are related party transactions, which are on an arm’s length basis. The Promoter/Promoter Group of the Company do not have any interest in the transaction.
3.	Industry to which the entity being acquired belongs	Health, Wellness & Personal care
4.	Objects and impact of acquisition	Satiya Nutraceuticals is a subsidiary of the Company, with Marico currently holding 60% stake on a fully diluted basis. The strategic investment in Satiya Nutraceuticals has expanded Marico’s total addressable market in the value-added foods and nutrition segments as well as presence in rapidly growing personal care and wellness categories. The current transaction is towards acquisition of the 38.18% stake held by Founders and certain other shareholders in Satiya Nutraceuticals, pursuant to the rights under the definitive agreement(s).
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None
6.	Indicative time period for completion of the transaction	Acquisition of 24.09% stake on a fully diluted basis was completed on October 5, 2026. Acquisition of the remaining 14.09% stake held by Founder and certain other shareholders will be completed in July 2027 subject to terms and conditions of the definitive agreements.
7.	Nature of consideration (cash consideration or share swap and details of the same)	Cash
8.	Cost of acquisition or the price at which the shares are acquired	Consideration of ₹ 1,012.03 Crores towards current tranche of acquisition of 24.09% stake in Satiya Nutraceuticals on a fully diluted basis. Accordingly, the aggregate consideration for acquisition of 84.09% stake on a fully diluted basis in Satiya Nutraceuticals stands at ₹ 1,392.07 Crores. The remaining stake of 14.09% held by Founder and certain other shareholders will be acquired for an aggregate consideration to be determined at such time which shall comprise a base consideration of up to ₹ 592 Crores and additional consideration subject to milestones, terms and conditions under the definitive agreement(s).

9.	Percentage of shareholding/control acquired and/or number of shares acquired	As part of the current tranche, the Company has acquired 24.09% stake, thereby increasing its aggregate stake from 60% to 84.09% on a fully diluted basis. The remaining 14.09% stake held by Founder and certain other shareholders will be acquired in July 2027, subject to terms and conditions of the definitive agreements.								
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, Country in which the acquired entity has presence	Satiya Nutraceuticals Private Limited, a company incorporated under the Companies Act 2013 on February 13, 2020 is headquartered at Mumbai, Maharashtra and owns ‘The Plant Fix – Plix’, a leading plant- based nutrition & personal care brand with a strong presence in rapidly growing health and wellness segments. Details of last 3 years’ Consolidated Turnover are as below: <table><tr><th>Year</th><th>Consolidated Turnover (₹ Crores)</th></tr><tr><td>FY 2025 – 26</td><td>864.31</td></tr><tr><td>FY 2024 – 25</td><td>432.84</td></tr><tr><td>FY 2023 – 24</td><td>155.32</td></tr></table>	Year	Consolidated Turnover (₹ Crores)	FY 2025 – 26	864.31	FY 2024 – 25	432.84	FY 2023 – 24	155.32
Year	Consolidated Turnover (₹ Crores)									
FY 2025 – 26	864.31									
FY 2024 – 25	432.84									
FY 2023 – 24	155.32									